It's an important milestone for gene editing technology: a novel treatment for sickle cell disease utilizing CRISPR-Cas9, has now received FDA approval – a first for this type of therapy.
ETH Zurich molecular biologist Mandy Boontanrart is researching gene therapies that could be used to cure two of the most common types of inherited anaemia: beta thalassaemia and sickle cell anaemia.
Combining questions about a person's health with data from smartwatch sensors, a new app can predict within minutes whether someone is infected with COVID-19.
A UK biotech laboratory has used mass spectrometry in a new approach to coronavirus testing. MAP Sciences developed a gargle test, which collects samples from the back of the throat, and avoids the unpleasant sensation of the current PCR (polymerase chain reaction) swab tests. From there, the sample is tested for coronavirus using mass spectrometry (MS) with high levels of accuracy.
A novel outpatient procedure offers lasting pain relief for patients suffering from moderate to severe arthritis in their hip and shoulder joints, according to a study presented at the annual meeting of the RSNA.
An up-and-coming gene therapy for blood disorders. A new class of medications for cystic fibrosis. Increased access to telemedicine. These are some of the innovations that will enhance healing and change healthcare in the coming year, according to a distinguished panel of clinicians and researchers from Cleveland Clinic. In conjunction with the 2020 Medical Innovation Summit, Cleveland Clinic…
A team from the Broad Institute of MIT and Harvard has developed a new CRISPR genome-editing approach by combining two of the most important proteins in molecular biology – CRISPR-Cas9 and a reverse transcriptase – into a single machine. The system, called “prime editing,” is capable of directly editing human cells in a precise, efficient, and highly versatile fashion. The approach…
The World Health Organisation's (WHO) Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. Now, updated versions of the two lists have been published, focusing on cancer and other global health challenges, with an emphasis on effective…
Help for patients with sickle cell disease may soon come from gene editing to fix the mutation that causes the disease and boost the patient's own protective fetal hemoglobin.
A proof-of-principle study shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells.
As Shimadzu celebrates its 50th anniversary in Europe, we spoke with Stéphane Moreau, Manager of LC-MS & Life Sciences at the Marketing Europe/Analytical Business Unit of Shimadzu Europa GmbH, about today’s and many more decades of exciting clinical developments.
A scientist has discovered a gene-editing technology that could efficiently and accurately correct the genetic defects that underlie certain diseases, positioning the new tool as the basis for the next generation of genetic therapies.
Although blood transfusion today is a well-established and safe procedure, the medical science community has not yet arrived at a consensus regarding appropriate patient blood management (PBM) methods. ‘Many PBM approaches have not yet been scientifically validated; consequently over- as well as under-transfusion might be associated with adverse events and complications for the patient,’…
Researchers in Germany have demonstrated that hematopoietic stem cell (HSC) transplants can be improved by treatments that temporarily prevent the stem cells from dying.
Every year around a quarter of a million children worldwide die from sickle cell disease. In Germany around 3,000 people suffer from this rare inherited blood disorder.
A team of researchers from Brown University, ETH Zurich, the Universita da Svizzera Italiana (USI) and Consiglio Nazionale delle Ricerche (CNR) is using America’s most powerful supercomputer to help understand and fight diseases affecting some of the body’s smallest building blocks.